Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
Conditions
Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Trial Timeline
Sep 5, 2018 → Oct 21, 2018
NCT ID
NCT03649165About Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen
Treatment A + Treatment B + Treatment C + Treatment D + Acetaminophen is a phase 1 stage product being developed by AstraZeneca for Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs). The current trial status is completed. This product is registered under clinical trial identifier NCT03649165. Target conditions include Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03649165 | Phase 1 | Completed |
Competing Products
20 competing products in Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Phase 2 | 52 |
| Selumetinib | AstraZeneca | Phase 1 | 33 |
| Selumetinib | AstraZeneca | Phase 1 | 33 |
| AZD2014 | AstraZeneca | Phase 2 | 52 |
| Selumetinib + Placebo | AstraZeneca | Phase 2 | 52 |
| Selumetinib | AstraZeneca | Phase 1/2 | 41 |
| Selumetinib | AstraZeneca | Phase 1 | 33 |
| Selumetinib granule formulation + Selumetinib capsule formulation | AstraZeneca | Phase 1/2 | 41 |
| Selumetinib | AstraZeneca | Phase 3 | 77 |
| Everolimus (RAD001) , Afinitor® | Novartis | Phase 2 | 52 |
| RAD001: Everolimus | Novartis | Phase 2 | 52 |
| RAD001, everolimus | Novartis | Phase 2 | 52 |
| Tasigna | Novartis | Phase 1 | 33 |
| Trametinib | Novartis | Phase 2 | 52 |
| Everolimus (RAD001) | Novartis | Phase 2 | 52 |
| Sutent®/Sunitinib | Pfizer | Phase 2 | 51 |
| Sorafenib (Nexavar) | Bayer | Phase 2 | 49 |
| PTC299 | United Therapeutics | Phase 2 | 49 |
| REC-2282 + Placebo | Recursion Pharmaceuticals | Phase 2/3 | 60 |
| Binimetinib | Pacific Biosciences | Phase 2 | 44 |